Skip to main content
Article thumbnail
Location of Repository

Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis

By Stella Pelengaris, Sylvie Abouna, Linda Cheung, Vasiliki Ifandi, Sevasti I. Zervou and Michael Khan


Background\ud Tumour regression observed in many conditional mouse models following oncogene inactivation provides the impetus to develop, and a platform to preclinically evaluate, novel therapeutics to inactivate specific oncogenes. Inactivating single oncogenes, such as c-Myc, can reverse even advanced tumours. Intriguingly, transient c-Myc inactivation proved sufficient for sustained osteosarcoma regression; the resulting osteocyte differentiation potentially explaining loss of c-Myc's oncogenic properties. But would this apply to other tumours?\ud \ud Results\ud We show that brief inactivation of c-Myc does not sustain tumour regression in two distinct tissue types; tumour cells in pancreatic islets and skin epidermis continue to avoid apoptosis after c-Myc reactivation, by virtue of Bcl-xL over-expression or a favourable microenvironment, respectively. Moreover, tumours progress despite reacquiring a differentiated phenotype and partial loss of vasculature during c-Myc inactivation. Interestingly, reactivating c-Myc in β-cell tumours appears to result not only in further growth of the tumour, but also re-expansion of the accompanying angiogenesis and more pronounced β-cell invasion (adenocarcinoma).\ud \ud Conclusions\ud Given that transient c-Myc inactivation could under some circumstances produce sustained tumour regression, the possible application of this potentially less toxic strategy in treating other tumours has been suggested. We show that brief inactivation of c-Myc fails to sustain tumour regression in two distinct models of tumourigenesis: pancreatic islets and skin epidermis. These findings challenge the potential for cancer therapies aimed at transient oncogene inactivation, at least under those circumstances where tumour cell differentiation and alteration of epigenetic context fail to reinstate apoptosis. Together, these results suggest that treatment schedules will need to be informed by knowledge of the molecular basis and environmental context of any given cancer.\ud \u

Topics: RC0254
Publisher: BioMed Central Ltd.
Year: 2004
OAI identifier:

Suggested articles


  1. (2001). Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. doi
  2. (2004). Adult pancreatic betacells are formed by self-duplication rather than stem-cell differentiation. Nature doi
  3. (1995). Cabrijan T: Multiple genetic alterations in malignant metastatic insulinomas. doi
  4. (2003). Cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer doi
  5. (1992). Chardonnet Y: c-myc and c-Ha-ras cellular oncogenes and human papillomaviruses in benign and malignant cutaneous lesions. doi
  6. (2001). Chodosh LA: cMYC induces mammary tumourigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med
  7. (2002). Chodosh LA: Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell doi
  8. (2003). Chodosh LA: Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumourigenesis. Genes Dev
  9. (2001). CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. doi
  10. (2004). Contag CH, Felsher DW: MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature doi
  11. (1999). DePinho RA: Essential role for oncogenic Ras in tumour maintenance. Nature doi
  12. (2004). DePinho RA: Molecular diversity of astrocytes with implications for neurological disorders. doi
  13. (2000). DG: Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet
  14. (2004). DW: Conditional animal models: a strategy to define when oncogenes will be effective targets to treat cancer. Semin Cancer Biol doi
  15. (2003). DW: Genomically complex lymphomas undergo sustained tumour regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood doi
  16. (2004). DW: Modeling the cancer patient with genetically engineered mice: prediction of toxicity from molecule-targeted therapies. Cancer Cell doi
  17. (2002). DW: Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science
  18. (2002). E: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. doi
  19. (2002). GI: c-Myc: more than just a matter of life and death. Nature- reviews cancer doi
  20. (2001). GI: Defining the temporal requirements for Myc in the progression and maintenance of skin neoplasia. Oncogene doi
  21. (2002). GI: Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell doi
  22. (2001). L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. doi
  23. (2004). LN: Protein kinase inhibitors: insights into drug design from structure. Science doi
  24. (1996). Pavelic ZP: Molecular genetics of malignant insulinoma. Anticancer Res
  25. (2003). Pharmacological inactivation of MYC for the treatment of cancer. Drug News Perspect doi
  26. (1999). Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell doi
  27. (1999). Reversible tumourigenesis by MYC in hematopoietic lineages. Mol Cell doi
  28. (2004). T: Reversible lymphomagenesis in conditionally c-MYC expressing mice. doi
  29. (2003). The c-myc oncogene in tumor progression. Crit Rev Oncog
  30. (1996). The rise and fall of apoptosis during multistage tumourigenesis: down-modulation contributes to tumour progression from angiogenic progenitors. Genes Dev doi
  31. (2001). Varmus HE: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumour suppressor genes. Genes Dev
  32. (2003). Varmus HE: Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumour maintenance. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.